Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)
Close on Nov 18, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Intellia Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$423.48M. For fiscal 2025 it was -$440.99M. The highest annual figure on record is -$13.41M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$440.99M | – |
| FY2024 | Dec 31, 2024 | -$534.26M | – |
| FY2023 | Dec 31, 2023 | -$515.29M | – |
| FY2022 | Dec 31, 2022 | -$458.16M | – |
| FY2021 | Dec 31, 2021 | -$267.85M | – |
| FY2020 | Dec 31, 2020 | -$136.58M | – |
| FY2019 | Dec 31, 2019 | -$106.37M | – |
| FY2018 | Dec 31, 2018 | -$90.87M | – |
| FY2017 | Dec 31, 2017 | -$69.56M | – |
| FY2016 | Dec 31, 2016 | -$32.16M | – |
| FY2015 | Dec 31, 2015 | -$13.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$112.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$100.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$98.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$111.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$110.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$120.81M | – |
| Q4 FY2024 | Dec 31, 2024 | -$136.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$144.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$139.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$114.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$139.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$131.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$132.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$111.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$110.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$105.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$98.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$144.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$80.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$71.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$69.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$46.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$42.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$33.05M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.33M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.46M | – |
| Q1 FY2019 | Mar 31, 2019 | -$23.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.75M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$23.60M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.88M | – |
| Q2 FY2017 | Jun 30, 2017 | -$16.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.82M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.70M | – |
See a number that looks wrong?